- Efficacy
- Patient case 1: Achieving optimal management while considering poor treatment compliance and renal function decline
- Patient case 2: Achieving optimal management in an elderly patient with declining renal function
- CV Protection
- Linagliptin Efficacy vs Other DPP4i ADC
- Simplicity
- Linagliptin Efficacy vs Other DPP4i FUE
- Linagliptin Efficacy Data
- Efficacy
- Explore Efficacy
- Efficacy of Linagliptin (Trajenta®) vs other DPP4i
- Dr. Mike Cummings 1 - Trajenta® consistently lowers HbA1c in line with other DPP4i
- Dr. Mike Cummings 4 - Trajenta® can be used in a broad range of patients whenever a DPP4i is needed
- Dr. Mike Cummings 5 - Trajenta® can be used across a heterogenous patient population when a DPP4i is needed
- Dr. Mike Cummings 6 - 55-year-old male; HbA1c 8%; on metformin; normal renal function; Trajenta® is an appropriate option when a DPP4i is needed
- Dr. Mike Cummings 3 - Trajenta® can be used in a broad range of T2D patients, independent of kidney function
- Ask the Expert: Prof. O'Brien on Efficacy
- Simplicity
- What are the key results of CARMELINA/CAROLINA and why is it unique vs other DPP4i CVOTs?
- Linagliptin Simplicity and Convenience ADC
- Dr. Esteban Jodar 07 - With CARMELINA®, the simplicity of Trajenta® is reinforced by the reinforced safety profile, established efficacy and the convenience of one dose once daily
- With CARMELINA®, linagliptin demonstrated a long-term cardiovascular safety profile in patients with T2D and showed no increase in risk of hospitalisation for heart failure
- Trajenta Recorded Webinar - Per Henrik Groop
- Limited to Kidney Video - Roger Chen
- Simplicity Believer Video - Ted Wu
- Simplicity of Trajenta
- Relevance of Linagliptin in 2021
- 10 Years of Simplicity with Linagliptin
- 10 Years of Simplicity in T2D Management
- Linagliptin: 10 Years of Simplicity in T2D Mgt
- 10 Years of Simplicity in T2D Management
- Linagliptin (Trajenta®) simplicity and convenience
- Limited to kidney video by Dr. Peter Lin
- Limited to kidney video by Prof. Roger Chen
- Dr. Mike Cummings 2 - Simplicity of Trajenta® within the DPP4i class
- Ask the Expert: Prof O'Brien on Broad Range of Patients
- NDPP4||Not All DPP4i are the Same
- CV and Renal Safety
- CARMELINA
- CARMELINA Trial Summary
- Linagliptin (Trajenta®) combines efficacy and good safety profile across a broad range of T2D patients
- CARMELINA Trial reinforces simplicity of use of Linagliptin (Trajenta®) in a broad range of T2D patients
- CARMELINA: CV and renal safety profile of Linagliptin (Trajenta®)
- What makes CARMELINA Trial unique versus other DPP4i CVOTS? by Dr. Alice Cheng
- CARMELINA Asian Subanalysis
- Carmelina CVOT Video
- Linagliptin is safe across T2D patient age groups, including the Elderly
- CARMELINA: Reinforces simplicity of Linagliptin (Trajenta®) in a broad range of T2D patients
- CARMELINA: Confirms long-term CV and renal safety of Linagliptin (Trajenta®) in CV and renal risk T2D patients
- CV and kidney safety of Linagliptin (Trajenta®) in asian patients
- CAROLINA
- CVOTs
- Linagliptin (Trajenta®): Demonstrated good safety profile in patients across the type 2 diabetes continuum based on its CVOTs
- Linagliptin's CVOT program provides evidence of its safety for a broad range of patients
- Linagliptin demonstrates efficacy & safety in T2D, including those with high CV & renal risk
- Linagliptin (TRAJENTA®): Simplicity in a broad range of patients
- CV and Kidney Safety of Linagliptin ina Asians ADC
- 4Q Trajenta OPD Video-SB-Mark Cooper
- Trajenta CVOT infographic
- CARMELINA
- Explore Safety
- Dr. Mike Cummings 7 - CARMELINA® is unique as it includes patients high cardiovascular risk and, in many instances, with impaired renal function
- Dr. Mike Cummings 8 - With CARMELINA®, linagliptin established the cardiovascular and kidney safety profile along with no risk of hospitalisation for heart failure
- Dr. Mike Cummings 9 - CARMELINA® reinforces the safety profile of linagliptin in a broad range of patients and supports the simplicity of use
- Dr. Mike Cummings 10 - CARMELINA® is the only study that included a kidney-related secondary end point. The study showed no difference in outcome between Trajenta® and placebo
- Trajenta - Alice Cheng - Combined - Interview Video
- CARMELINA
- Prescribing Information
- Dosing Convenience
- Experience
- Safety
- Ask the Expert: Prof. O'Brien on CV Safety
- Ask the Expert: Prof. O'Brien on Renal Safety
- Treatment with Linagliptin (TRAJENTA®) on top of SOC resulted to lesser CV and renal events
- NDPP4||ASK-TRA-T2D-RED-2||Real-world evidence_Fragment
- NDPP4||Expert Video Series: What makes CARMELINA stand out vs other DPP4i CVOTs
- NDPP4||Expert Video Series: CAROLINA - the only CVOT with an active comparator, glimepiride
- Elearning
